06:35:55 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 X-dag ordinarie utdelning GTAB B 0.00 SEK
2024-05-29 Årsstämma
2024-05-23 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-11-16 Extra Bolagsstämma 2023
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 X-dag ordinarie utdelning GTAB B 0.00 SEK
2023-05-30 Årsstämma
2023-05-24 Kvartalsrapport 2023-Q1
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-06-01 X-dag ordinarie utdelning GTAB B 0.00 SEK
2022-05-31 Årsstämma
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-09 X-dag ordinarie utdelning GTAB B 0.00 SEK
2021-06-08 Årsstämma
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-06-12 X-dag ordinarie utdelning GTAB B 0.00 SEK
2020-06-11 Årsstämma
2020-05-20 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-23 X-dag ordinarie utdelning GTAB B 0.00 SEK
2019-05-22 Årsstämma
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-21 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-05-31 X-dag ordinarie utdelning GTAB B 0.00 SEK
2018-05-30 Årsstämma
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-06-02 X-dag ordinarie utdelning GTAB B 0.00 SEK
2017-06-01 Årsstämma
2017-05-23 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-06-10 X-dag ordinarie utdelning GTAB B 0.00 SEK
2016-06-09 Årsstämma
2016-05-20 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-06-10 X-dag ordinarie utdelning GTAB B 0.00 SEK
2015-06-09 Årsstämma
2015-05-22 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-06 X-dag ordinarie utdelning GTAB B 0.00 SEK
2014-06-05 Årsstämma
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-06 Bokslutskommuniké 2013
2013-11-22 Kvartalsrapport 2013-Q3
2013-08-23 Kvartalsrapport 2013-Q2
2013-05-31 X-dag ordinarie utdelning GTAB B 0.00 SEK
2013-05-30 Årsstämma
2013-05-15 Kvartalsrapport 2013-Q1
2013-02-07 Bokslutskommuniké 2012
2012-11-01 Kvartalsrapport 2012-Q3
2012-09-28 Kapitalmarknadsdag 2012
2012-08-22 Kvartalsrapport 2012-Q2
2012-06-15 X-dag ordinarie utdelning GTAB B 0.00 SEK
2012-06-14 Årsstämma
2012-05-10 Kvartalsrapport 2012-Q1
2012-02-08 Bokslutskommuniké 2011
2011-11-01 Kvartalsrapport 2011-Q3
2011-08-23 Kvartalsrapport 2011-Q2
2011-06-15 X-dag ordinarie utdelning GTAB B 0.00 SEK
2011-06-14 Årsstämma
2011-04-27 Kvartalsrapport 2011-Q1
2011-01-26 Bokslutskommuniké 2010
2010-10-29 Kvartalsrapport 2010-Q3
2010-08-20 Kvartalsrapport 2010-Q2
2010-06-09 X-dag ordinarie utdelning GTAB B 0.00 SEK
2010-06-08 Årsstämma
2010-04-30 Kvartalsrapport 2010-Q1
2010-02-05 Bokslutskommuniké 2009
2009-10-30 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaNGM
SektorHälsovård
IndustriLäkemedel & Handel
Glycorex Transplantation är verksamt inom bioteknik. Bolaget bedriver forskning, utveckling och marknadsföring inom området för organtransplantation. Bolagets huvudprodukt Glycosorb-ABO möjliggör transplantationer oavsett blodgrupp hos givare respektive mottagare. Transplantation med hjälp utav bolagets produkt utförs på global nivå. Glycorex Transplantation grundades år 1996 och har sitt huvudkontor i Lund.
2022-08-26 08:00:00

Accelerating sales growth

"Glycorex had a strong second quarter of 2022 with solid double-digit growth. Demand grew as the effects of the COVID-19-pandemic continued to subside which, combined with an effective implementation of the company's G4G strategy, delivered a very good quarter."  - Geert Nygaard, CEO

Financial information

April - June 2022
  • Net sales: SEK 11.2 million (8.0)
  • Operating income: SEK -1.7 million (-2.2)
  • Net income for the period: SEK -1.7 million (-2.3)
  • Earnings per share: SEK -0.02 (-0.03)
Events in the second quarter
  • Distributor agreement in Chile. Initiated marketing efforts.
  • Registration of Glycosorb® ABO in South Africa. First order for Glycosorb® ABO from distributor.
  • New transplant centers added in England and India.
  • Participation as an exhibitor at the ATC (American Transplant Congress) in Boston.
  • Indian customer reports successful blood group incompatible liver transplantation from a living donor using Glycosorb® ABO.
  • Order of Glycosorb® ABO from reputable centers in England for the treatment of Pure Red Cell Aplasia after a blood group incompatible bone marrow transplant.
  • Meetings with potential Glycosorb® UBP key customers in key European markets.
  • Delivery of the Glycosorb® UBP to two European reference centers for evaluation.
  • Positive initial results obtained for the reduction of anti-A/B antibodies on platelet concentrate. 
  • Announcement of partner in the Rheumatoid Arthritis project.
Significant events after the balance sheet date
  • The CEO of Glycorex Transplantation AB (publ) resigns his employment.

THE ENTIRE INTERIM REPORT FOR QUARTER 2 2022 IS ATTACHED

For further information, please contact:

Glycorex Transplantation AB (publ)

Scheelevägen 27

SE-223 63 Lund, Sweden

Phone: +46 46 286 5230

info@glycorex.com

glycorex.com

This information is such information that Glycorex Transplantation AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on August 26, 2022 at 08.00 CET.

Brief information about the company

Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.

The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.